Skip to content
Kernal Biologics logo

Kernal Biologics

Kernal Biologics is a YC Summer 2020 (S20) company. Based in Cambridge, MA, USA. Team of 20.

  • Artificial Intelligence
  • Biotech
  • Genomics

About Kernal Biologics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Kernal Biologics develops mRNA-based in vivo cell therapies for cancer and autoimmune diseases. Its platform uses T-cell-targeted lipid nanoparticles combined with AI-designed selective translation to program CAR-T cells directly inside the body, replacing the costly, slow, and clinic-restricted process of manufacturing cell therapies ex vivo. The lead program, KR-402, delivers mRNA with high efficiency to T cells, enabling direct B-cell depletion without extracting and reengineering a patient's cells outside the body.

Go-to-market

Kernal Biologics pursues partnerships alongside internal pipeline development, targeting biopharmaceutical collaborators and advancing programs toward clinical translation in oncology and autoimmune indications.

From the Y Combinator listing

How Kernal Biologics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Kernal is creating mRNA 2.0 therapies that work in specific cells

Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Cambridge, MA, USA
Team size
20
Status
Active
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works